Hemab Therapeutics

Executive Summary

Hemab Therapeutics is a clinical-stage biotechnology company based in Copenhagen, Denmark, focused on developing first-in-class preventative treatments and functional cures for rare bleeding and thrombotic disorders. Founded in 2019, the company leverages a proprietary antibody-based platform to create targeted biologics that restore hemostatic balance. Hemab's mission is to transform care from reactive management to proactive prevention, addressing conditions that have seen limited therapeutic innovation for decades. With its lead program advancing in Phase 3, Hemab is poised to potentially change the treatment paradigm for patients with life-threatening bleeding disorders. Hemab's pipeline includes investigational therapies for hemophilia and other rare coagulation disorders. The company is currently conducting a pivotal Phase 3 trial for its lead candidate, which targets unmet needs in hemophilia A and B. Positive data from this study could support regulatory filings and potentially lead to the first approved therapy for this indication from Hemab. Additionally, Hemab is advancing earlier-stage programs for thrombotic thrombocytopenic purpura (TTP) and other rare conditions. The company's strong preclinical and clinical data, combined with a robust platform, position it for significant value creation in the near term. Upcoming catalysts include key data readouts and potential strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line data for lead hemophilia candidate65% success
• Q2 2026Initiation of Phase 2/3 trial for TTP candidate80% success
• Q3 2026Potential partnership or licensing deal for antibody platform50% success